Laverock Therapeutics secures Innovate UK award to advance immune effector cell therapeutics programme using GEiGS® technology

Laverock Therapeutics secures £1m funding via the Innovate UK Investor Partnerships Future Economy programme, supported by UKI2S. 

Laverock Therapeutics, developer of a unique gene silencing platform for the creation of programmable advanced therapies, is pleased to announce that it has been awarded £1m in funding, made up of a £700k grant from Innovate UK, the UK’s innovation agency, and co-funded by Innovate UK cancer therapeutics programme via their investor partnership programme, with UK Innovation and Science Seed Fund (UKI2S) acting as the investor partner. The award will enable Laverock to progress its immune effector cell therapeutic programme aiming to combat hard-to-treat cancers, via use of its gene editing induced gene silencing (GEiGS®) technology.


The Innovate UK and UKI2S funded project will provide access to patient derived, highly disease relevant experimental tools. This will aid preclinical evaluation and the generation of key data in support of Laverock’s programmable macrophage and T-cell programmes developed using its unique GEiGS technology. This will facilitate informed decision making on the selection of future oncology therapeutic candidates.


Support from Innovate UK and UKI2S will also allow Laverock to strengthen internal capabilities in immune oncology by building an oncology focused team and facilitating collaboration with leading centres of excellence. These collaborations will focus on patients’ needs and enable the development of more targeted therapeutic products for the communities that will benefit.


Tim Allsopp, Chief Technology Officer of Laverock Therapeutics, said, ‘We’re tremendously excited by this achievement and the public-private endorsement of our technology that Innovate co-funding provides. We’d like to thank Innovate UK and UKI2S for their support and look forward to integrating our novel gene silencing GEiGS® platform into more effective therapeutic designs for the benefit of the global cancer patient community.’


Oliver Sexton, UKI2S Investment Director, added, ‘UKI2S is delighted to invest alongside Innovate UK as a member of the Investor Partnerships scheme. As an investor, Innovate UK’s support for additional programmes provides a powerful tool to accelerate development and de-risk investment. Innovate UK and UKI2S’s equity is helping Laverock add to its pipeline of ground-breaking therapies.’


This award follows the company’s recent expansion of its seed funding round to £13.5m.


ENDS


For further information please contact:


Laverock Therapeutics

E: contact@laverocktx.com

 

Sciad Communications

E: pressteam@sciad.com

T: +44 (0)20 3405 7892


Notes to Editors


About Laverock Therapeutics
Laverock Therapeutics is developing a unique gene silencing platform for the creation of programmable advanced therapies. The company was established in 2021 to commercialise the gene editing induced gene silencing (GEiGS) technology for human therapeutic applications. GEiGS provides significant advantages over current approaches allowing generation of products with improved efficacy, safety and accessibility.

 

About GEiGS®

GEiGS uses universal gene editing tools to minimally edit non-coding genes and redirect their silencing activity (RNAi) towards a new target gene. GEiGS is strongly differentiated from other gene silencing approaches through its core stable, tunable and programmable attributes, ensuring cell type- or condition-specific activity.

For more information, please visit www.laverocktx.com and follow us on LinkedIn. 

 

About Innovate UK

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas.

We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth.

We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions.

Innovate UK is part of UK Research and Innovation. For more information visit www.ukri.org/councils/innovate-uk/

Laverock Therapeutics to Present New Data on Programmable, Tunable, Stable and Specific Gene Silencing Platform at ESGCT

October 22, 2024
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October. Led by COO Tom Payne, Laverock’s team of scientists will be presenting three posters covering the Company’s technology platform and its application to CAR T cells and tumour microenvironment (TME) responsive macrophages for oncology. The data demonstrates the broad utility of the gene silencing technology for the development of differentiated therapeutic products. In contrast to other approaches, Laverock’s technology allows gene silencing that is programmable – linking silencing to cell identity or state; tunable – giving precise control of gene expression; stable – avoiding transient affects or epigenetic silencing; and specific – showing minimal loss or gain of function effects. It is also readily multiplexable, allowing targeting of multiple pathways in a single engineering step. Laverock’s product-focused posters demonstrate tunable, multiplex silencing of checkpoint pathways in primary T-cells, and use of phenotype-specific miRNA expression patterns to control macrophage function in response to TME cues. Tom Payne, COO of Laverock, said: “Over the last year we have generated a complete set of data in human cells demonstrating the unique features of our technology – namely its ability to silence genes in a programmable, tunable, stable and highly specific manner across a number of target genes and cell types. We believe this will enable the development of safer, targeted cell therapies by engineering human cells that exhibit gene silencing of the right genes, in the right cell, and at the right time.” Poster presentations: P: 0653. Klucnika, A et al Gene Editing induced Gene Silencing (GEiGS®) - A new technology to transform advanced therapies by programmable gene silencing. (Thursday 24.10.24 14:15 – 15:30). P: 0694. Houghton, B et al Programmable, multiplex CAR T cell engineered with Genome Editing induced Gene Silencing (GEiGs). (Thursday 24.10.24 18:00 – 19:30). P:0780. Menon, V et al Gene Editing induced Gene Silencing (GEiGS) technology to develop TME-responsive macrophages for solid tumour immunotherapy. (Thursday 24.10.24 18:00 – 19:30). ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries: Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting oncology and genetic diseases – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .

Laverock Therapeutics makes significant advances in its unique programmable gene silencing platform and announces pipeline focus on advanced therapies in oncology and genetic diseases

By Juliette Craggs • September 26, 2024
Programmable, tunable, stable and specific gene silencing has been demonstrated across multiple target genes and multiple cell types PoC achieved with concomitant silencing of more than one gene Industrialisation of platform processes delivering significant increase in throughput Strategic in-house focus on development of pipeline of programmable advanced therapies in oncology and genetic disease Potential additional application to multiple high impact therapeutic areas through partnering including, hypoimmunogenicity/type 1 diabetes, inflammatory diseases and fibrosis

Laverock Therapeutics announces forthcoming investor, scientific and partnering conference schedule

September 5, 2024
Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024. Forthcoming events include: ISCT Europe Regional Meeting , 4 – 6 September in Gothenburg - speaking Healthtech Innovation Day , 17 – 18 September in Paris - speaking, investor meetings Sachs Biotech in Europe Forum , 25 – 26 September in Basel - speaking, investor meetings and partnering Chardan Genetics Medicines Conference , 30 September – 1 October in New York - speaking, investor meetings and partnering ARM Meeting on the Mesa , 7 – 9 October in Phoenix, AZ – speaking, investor meetings and partnering TechBio UK 2024 , 16 October in London - panellist ESGCT Congress , 22 – 25 October in Rome - scientific presentations BioEurope , 4 – 6 November in Stockholm - investor meetings and partnering Cell 2024 , 6 – 8 November in London - speaking, session chair, panellist David Venables, CEO of Laverock, said: “We are excited to be showcasing recent advances in our technology at a number of key investor, scientific and partnering events. Over the course of 2024, Laverock has further validated its platform’s ability to silence genes in a programmable, tunable, stable and highly specific manner across multiple target genes and cell types. We have also broadened the platform’s potential by demonstrating the ability to silence more than one gene concomitantly. These developments further expand the range of potential applications for Laverock’s technology.” To arrange meetings with the Laverock leadership team at any of these events, please contact: contact@laverocktx.com ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries : Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
More Posts
Share by: